You are here

  • Home
  • Archive
  • Volume 11, Issue 7
  • Nivolumab and ipilimumab with concurrent stereotactic radiosurgery for intracranial metastases from non-small cell lung cancer: analysis of the safety cohort for non-randomized, open-label, phase I/II trial

Article metrics

Article menu

This article has a correction. Please see:

Clinical/translational cancer immunotherapy
Original research
Nivolumab and ipilimumab with concurrent stereotactic radiosurgery for intracranial metastases from non-small cell lung cancer: analysis of the safety cohort for non-randomized, open-label, phase I/II trial

 

Online download statistics by month:

Online download statistics by month: July 2023 to August 2025

AbstractFullPdf
Jul 202311681175203
Aug 202349749972
Sep 202336136267
Oct 202325625668
Nov 202326226275
Dec 2023273274133
Jan 2024244244124
Feb 202419919991
Mar 2024272273106
Apr 2024238240109
May 202424524794
Jun 2024236236106
Jul 202422722877
Aug 202419419569
Sep 202423323686
Oct 202424424499
Nov 202423823994
Dec 2024276281134
Jan 202524224277
Feb 2025301301111
Mar 202523323398
Apr 202521621678
May 202522722779
Jun 202516616661
Jul 2025440
Aug 2025110
Total705370802311